Cytokinetics, Incorporated CYTK
Set alert
62.72 USD +0.69 +1.11%
As of Nov 3, 11:42 AM ET
62.05 Day range 64.37
58.05 52-week range 88.31
- YTD
- -1.29%
- 1 year
- +4.48%
- Open
- 62.74
- Prev close
- 62.03
- Mkt cap
- 8.72B
- Vol
- 601.80K
- Avg vol
- 1.90M
- EPS
- -7.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 62.05
- High
- 64.37
- Forward P/E
- -14.09
- Beta
- 0.47
- Short ratio
- 8.18
- Inst. own
- 126.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 67.50
- 200-d avg
- 70.08
- 1y target
- 107.39
1Y chart
Events in this range
- Nov 5, 2025Earnings: -2.55; estimate -1.59; surprise -60.38%
- Feb 24, 2026Earnings: -1.5; estimate -1.48; surprise -1.35%
- May 5, 2026Earnings: -1.67; estimate -1.67; surprise 0%
- Aug 6, 2026Earnings: -1.5; estimate -1.63; surprise 7.98%
- Aug 13, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 13, 2026Rating: Barclays · Overweight → Overweight
- Aug 31, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 8, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 16, 2026Rating: William Blair · — → Outperform
- Oct 19, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (64)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 13, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 5, 2026 | 4 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 15, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 29, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jul 2, 2026 | 4 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | May 27, 2026 | 5 months ago |
Newest 20 of 64.
Key statistics
- Market cap
- 8.62B
- Enterprise value
- 9.02B
- Trailing P/E
- 0.00
- Forward P/E
- -14.09
- PEG ratio
- 0.00
- Price / sales
- 127.44
- Price / book
- 0.00
- EPS (TTM)
- -7.22
- Beta
- 0.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 67.67M
- Revenue growth
- -57.10%
- Free cash flow
- -397.41M
- Total cash
- 1.17B
- Total debt
- 1.42B
- Return on equity
- 0.00%
- Shares outstanding
- 139.02M
- Short % of float
- 20.46%
- 50-day average
- 67.50
- 200-day average
- 70.08
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 107.39 +71.2% upside
Now 62.72
- Target (low)
- 81.00
- Target (mean)
- 107.39
- Target (high)
- 140.00
Ratings (0m) 22 20 buy · 2 hold · 0 sell
- Strong buy7
- Buy13
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -1.41.
Financials — quick view
CYTK Revenue — quarterly 28.62M
CYTK Net income — quarterly -198.76M
CYTK EPS — quarterly -1.50
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -1.44 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -1.63 | -1.50 | +0.13 | +7.98% |
| May 5, 2026 | Mar 31, 2026 | -1.67 | -1.67 | 0.00 | 0.00% |
| Feb 24, 2026 | Dec 31, 2025 | -1.48 | -1.50 | -0.02 | -1.35% |
| Nov 5, 2025 | Sep 30, 2025 | -1.59 | -2.55 | -0.96 | -60.38% |
| Aug 7, 2025 | Jun 30, 2025 | -1.34 | -1.12 | +0.22 | +16.42% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 31, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2026 | Barclays | main | Overweight | Overweight |
| Aug 13, 2026 | JP Morgan | main | Overweight | Overweight |
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cytokinetics.com
News
- Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
- Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
- Baron Health Care Fund Q3 2026 Top Contributors And Detractors
- Contrasting Actinium Pharmaceuticals (NYSE:ATNM) and Cytokinetics (NASDAQ:CYTK)
- Cytokinetics to Announce Third Quarter Results on November 4, 2026
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
- HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target
- Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Your note
Sign in to keep a note on CYTK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BHANJI MUNA | Director | Stock Award(Grant) | May 26, 2026 | 26,361 |
| BLUM ROBERT I | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 11, 2026 | 282,710 |
| CALLOS ANDREW | Officer | Conversion of Exercise of derivative security | Aug 30, 2026 | 58,555 |
| HARRINGTON ROBERT ARTHUR | Director | Stock Award(Grant) | Oct 15, 2026 | 22,127 |
| HENDERSON JOHN TANNAHILL | Director | Stock Award(Grant) | Oct 15, 2026 | 78,795 |
| HESSEKIEL JEFFREY J | Officer | Stock Award(Grant) | Mar 12, 2026 | 107,943 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.15% | 20,094,362 | 1.25B | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 15.04% | 18,718,498 | 1.16B | Jun 29, 2026 |
| Wellington Management Group, LLP | 5.57% | 6,931,770 | 429.98M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.39% | 6,711,799 | 416.33M | Jun 29, 2026 |
| State Street Corporation | 5.22% | 6,494,233 | 402.84M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.92% | 6,117,515 | 379.47M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 5.05% | 6,285,983 | 389.92M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.98% | 4,952,045 | 307.18M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.47% | 4,314,356 | 267.62M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.81% | 3,491,654 | 216.59M | Sep 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.69% | 3,341,262 | 207.26M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.50% | 3,114,802 | 193.21M | Jun 29, 2026 |